SCHEMBL4420210

SCHEMBL4420210

COc1ccc(-c2nc(COC3CCN(C(=O)OC(C)(C)C)CC3)no2)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.49
EPHA2 P29317 1/20 0.43
KDR P35968 1/20 0.43
EPHB4 P54760 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
STS P08842 2/20 0.42
EPHX2 P34913 1/20 0.42
HTT P42858 2/20 0.41
NPBWR1 P48145 1/20 0.41
MCHR1 Q99705 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
HSD17B10 Q99714 1/20 0.41
DYRK1A Q13627 1/20 0.40
CHEK2 O96017 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411706 0.91 GPR119 (0.49) GPR119MEN1KMT2AALDH1A1STS
SCHEMBL4412961 0.86 GPR119 (0.48) GPR119
SCHEMBL4266520 0.84 GPR119 (0.47) GPR119EPHA2KDREPHB4MEN1
SCHEMBL4413084 0.82 GPR119 (0.47) GPR119EPHA2KDREPHB4MEN1
SCHEMBL4414163 0.82 GPR119 (0.47) GPR119
SCHEMBL4415880 0.81 GPR119 (0.46) GPR119EPHA2KDREPHB4MEN1
SCHEMBL4423389 0.81 GPR119 (0.49) GPR119EPHA2KDREPHB4PDE4B
SCHEMBL4421874 0.81 GPR119 (0.53) GPR119STS
SCHEMBL4411657 0.80 GPR119 (0.50) GPR119EPHA2KDREPHB4ALDH1A1
SCHEMBL4418527 0.80 GPR119 (0.58) GPR119STSMCHR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885EPHA2 766/4885KDR 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.